Safety and Efficacy of Exenatide as Monotherapy and Adjunctive Therapy to Oral Antidiabetic Agents in Adolescents With Type 2 Diabetes

NCT00658021 on ClinicalTrials.gov · last registry update 2020-12-01

A small phase 3 — 122 participants, against a typical 424. The sponsor logged completion for 18 April 2019. Primary outcome, as filed: Adjusted Change From Baseline in Glycated Hemoglobin A1c (HbA1c) at Week 28. exenatide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status: COMPLETED
Phase: P3
Drug: exenatide
Bydureon, Byetta
Sponsor: AstraZeneca
Sponsor type: Industry
Enrollment: 122
Started: 2008-05-30
Primary completion: 2019-04-18 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Adjusted Change From Baseline in Glycated Hemoglobin A1c (HbA1c) at Week 28

Conditions studied

Type 2 Diabetes

Every field above is taken directly from the registry record. See all detected changes across the class, or the exenatide page for this molecule’s full trial and approval history.